Strategic alliances and commericialization agreements aim to provide space for innovative solutions to accelerate breakthrough discoveries in cancer research while developing deeper relationships with companies that share a similar vision. This can be done through joint development opportunities, collaborations, licensing or a combination of these elements.
(This is not a comprehensive list of all active strategic and commercialization partners of MD Anderson Cancer Center.)
Exclusive strategic clinical deveopment and commercialization collaboration to evaluate Affimed's TandAb technology in combination with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.
MD Anderson and Spectrum Pharmaceuticals sign a licensing agreement that covers discoveries by MD Anderson researchers about the company's drug Poziotinib, a targeted therapy for lung cancer.
MD Andeson and Blue Print Medicines announce strategic collaboration to accelerate development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2).
MD Anderson and BridgeBio Pharma launch Navire Pharma to develop targeted therapyfor patients with difficult-to-treat cancer.
MD Anderson and Taiho Pharmaceutical announace collaboration to accelerate development of novel therapies for brain metastasis and other unmet needs.
MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer.
MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI.
MD Anderson and Varian partner to optimize radiation oncology treatment.